Eiko Lifesciences News

Swaraj Shares and Securities Pvt. Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement in accordance with the provisions of Regulations 13(4), 14(3) and 15(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended to the public shareholders of Eiko Lifesciences Ltd ("Target Company").

Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018

The Company is in receipt of a Public Announcement regarding Open Offer.

Swaraj Shares and Securities Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Revised Public Announcement under the provisions of Regulations 3(1), read with Regulations 13 (1), 14, and 15 (1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto for the attention of the public shareholders of Eiko Lifesciences Ltd ("Target Company").

A company is in receipt of a Public Announcement regarding Open Offer.

Swaraj Shares and Securities Pvt. Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement under the provisions of Regulations 3(1), read with Regulations 13 (1), 14, and 15 (1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto for the attention of the public shareholders of Eiko Lifesciences Ltd ("Target Company").

Closure of Trading Window

Company has incorporated a Limited Liability Partnership namely Eiko Scientific Solutions LLP under LLPIN : ACH-4311

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laxmikant Kabra HUF

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laxmikant Kabra HUF

In terms of Regulation 24(A)of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Annual Compliance Report.

Newspaper Publication

Statement on Deviation or Variation of funds under Regulation 32 of SEBI (LODR) Regulations, 2015

Appointment of Secretarial Auditor

Appointment of Internal Auditor

Audited Financial Results for quarter and year ended 31st march,2024

Please refer to attached PDF

Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 ,inter alia, to consider and approve This is to inform you that as required under Regulation 29 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015, the meeting of Board of Directors of the Company is scheduled to be heldon Monday, 13th May,2024 inter-alia, to consider and approve the following:1. The Audited Financial Results of the Company for the quarter and financial year ending on 31stMarch,2024 in accordance with Regulation 33 of the SEBI Listing Regulation.2. Any other matter with the permission of the chair

Update on Acquisition

Pursuant to regulation 40(10) of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 , We enclosed the certificate for the year ended 31st March 2024 issued by Shravan A. Gupta & Associates , Practicing Company Secretary in compliance with Regulation 40(9)of SEBI (Listing Obligation & Disclosure Requirements ) Regulations, 2015 for your information and record.

This is to certify that Bigshare Services Private Limited ,Registrar & Share Transfer Agent (RTA) Registered with Security Exchange Board of India (SEBI) vide Registration No.:INR000001385 is the Registrar & Share Transfer Agent (RTA) of the company and all activities in relation to share transfer facility are being maintained with them

Certificate under Reg.74 (5) of SEBI (DP) Regulation, 2018

Intimation of Trading Window Closure

Outcome of the Right issue Committee Meeting held on 19th March,2024

01st (First) Reminder Notice for Payment of First and Final Call Money

Statement on Deviation or Variation of Funds under Regulation Regulation 32 of SEBI (LODR)2015

Financial Results for quarter and nine months ended 31st December,2023

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Thursday, 08th February, 2024, Board, inter-alia, considered and approved the Unaudited Financial Results for the Quarter and nine months ended 31st December,2023.The Statutory Auditors have carried out a 'Limited Review' of the Unaudited Financial Results for the Quarter and nine months ended 31st December 2023. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company

Approved sending of a Reminder Notice to partly-paid up shareholders on which First and Final call Money remains unpaidDetails enclosed

In response to the BSE e-mail dated 02nd February,2024, we are re-submitting the revised corporate announcement with necessary changes

Intimation of Right Issue Committee Meeting of the Board of Directors to be held on 08th February,2024 to discuss the matters relating to post First and Final Call Money Procedures and who failed to pay their First and Final Call Money Procedures and who failed to pay their first call money within due date.

Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve This is to inform you that as required under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 08th February, 2024 inter-alia, to consider and approve the following:1. The Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2023 2. Any other matter with the permission of the chair.

1. To convert 3353121 partly paid rights equity shares to the eligible shareholders of the Company pursuant to payment made with respect to the First and Final Call issued by the Company2. To make application to National Securities Depository Limited and Central Depository Services (India) Limited3. To avail listing and trading approval from BSE Limited pursuant to conversion of partly paid up shares

We are pleased to update that our Company has officially entered into definitive business agreement with Vivacious Pharmatex Private Limited for developing and marketing of products under new segment i.e., Oleochemicals and allied business

Compliance Certificate Under 74(5) of SEBI DP Regulations, 2018

Submission of Corrigendum to the Advertisement for First and Final Call Notice in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015.

The Company has approved the revision of call money payment period for its first and final call as below:Call money period begin date: 03rd January, 2024Call money period end date: 17th January, 2024

First and Final Call Money Notice (ISIN: IN9666Q01014)Dispatch Completion and Newspaper Advertisement

First and Final Call Money Notice (ISIN:IN9666Q01014)Dispatch Completion and Newspaper Advertisement

First and Final Call Money Notice